---
title: "Decoy Therapeutics holds annual shareholder meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292818231.md"
description: "Decoy Therapeutics held its annual shareholder meeting on July 14, 2026. Shareholders approved the board's slate of Class II director nominees and ratified Ernst & Young as the independent registered public accounting firm for the fiscal year ending December 31, 2026."
datetime: "2026-07-15T21:15:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292818231.md)
  - [en](https://longbridge.com/en/news/292818231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292818231.md)
generator: "portal-rs"
---

# Decoy Therapeutics holds annual shareholder meeting

-   Decoy Therapeutics held its annual shareholder meeting on July 14, 2026. \* Shareholders backed the board’s slate of Class II director nominees. \* Shareholders ratified Ernst & Young as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-304949), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DCOY.US](https://longbridge.com/en/quote/DCOY.US.md)

## Related News & Research

- [Jefferies declares Q3 2026 distribution of R$ 1.4 per unit, payable Sept. 3](https://longbridge.com/en/news/297683771.md)
- [AGNT declares Q3 2026 dividend of R$ 0.04 per unit, payable Sept. 3](https://longbridge.com/en/news/297698793.md)
- [Oruka Therapeutics CEO Lawrence Klein sells USD 6.85 million in common shares](https://longbridge.com/en/news/297705054.md)
- [Abeona Therapeutics director Mark Alvino disposes of 15,000 common shares worth $87,966](https://longbridge.com/en/news/297702333.md)
- [ProQR Therapeutics held annual shareholder meeting in Amsterdam](https://longbridge.com/en/news/297613300.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**